Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela R Wateska

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
BMC Infectious Diseases|January 27, 2018
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysisAngela R Wateska, Mary Patricia Nowalk, Richard K Zimmerman, et al.
American Journal of Preventive Medicine|March 19, 2013
Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adultsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
JAMA|February 24, 2012
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccineKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Human Vaccines & Immunotherapeutics|August 17, 2012
Modeling the economic value of a Chagas' disease therapeutic vaccineBruce Y Lee, Kristina M Bacon, Angela R Wateska, et al.
Vaccine|October 7, 2010
Forecasting the economic value of an Enterovirus 71 (EV71) vaccineBruce Y Lee, Angela R Wateska, Rachel R Bailey, et al.
Journal of the National Medical Association|June 8, 2019
Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.SMary Patricia Nowalk, Angela R Wateska, Chyongchiou Jeng Lin, et al.
American Journal of Preventive Medicine|June 21, 2021
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. SeniorsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Infectious Diseases and Therapy|July 13, 2022
Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USAKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine|June 14, 2023
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adultsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Vaccine|July 13, 2010
Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenzaBruce Y Lee, Rachel R Bailey, Ann E Wiringa, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
BMC Infectious Diseases|January 27, 2018
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysisAngela R Wateska, Mary Patricia Nowalk, Richard K Zimmerman, et al.
American Journal of Preventive Medicine|March 19, 2013
Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adultsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
JAMA|February 24, 2012
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccineKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Human Vaccines & Immunotherapeutics|August 17, 2012
Modeling the economic value of a Chagas' disease therapeutic vaccineBruce Y Lee, Kristina M Bacon, Angela R Wateska, et al.
Vaccine|October 7, 2010
Forecasting the economic value of an Enterovirus 71 (EV71) vaccineBruce Y Lee, Angela R Wateska, Rachel R Bailey, et al.
Journal of the National Medical Association|June 8, 2019
Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.SMary Patricia Nowalk, Angela R Wateska, Chyongchiou Jeng Lin, et al.
American Journal of Preventive Medicine|June 21, 2021
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. SeniorsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Infectious Diseases and Therapy|July 13, 2022
Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USAKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine|June 14, 2023
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adultsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Vaccine|July 13, 2010
Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenzaBruce Y Lee, Rachel R Bailey, Ann E Wiringa, et al.
Pageof 5